Related Experiment Videos
Parenteral nitrogen mustard for inflammatory arthritis
1Department of Rheumatic and Immunologic Disease, Cleveland Clinic Foundation, Ohio 44195.
Cleveland Clinic Journal of Medicine
|October 1, 1990
Summary
Psoriatic arthritis patients refractory to methotrexate may benefit from intravenous nitrogen mustard (HN2). This chemotherapy agent showed comparable improvement to rheumatoid arthritis patients, suggesting a potential alternative treatment.
Area of Science:
- Rheumatology
- Oncology
Background:
- Psoriatic arthritis is a chronic inflammatory disease.
- Methotrexate is a common treatment but can be ineffective for some patients.
Observation:
- A single patient with severe psoriatic arthritis, resistant to methotrexate, received intravenous nitrogen mustard (HN2).
- The patient's response was compared to five rheumatoid arthritis patients receiving the same HN2 regimen.
Findings:
- The psoriatic arthritis patient demonstrated significant clinical improvement within 14 days of initiating HN2 therapy.
- The observed improvement was comparable to that seen in the rheumatoid arthritis patient cohort.
Implications:
- Intravenous HN2 presents a potential alternative therapeutic option for managing progressive psoriatic arthritis refractory to methotrexate.
- Further research is warranted to confirm the efficacy and safety of HN2 in psoriatic arthritis treatment.